Introduction
Epilepsy is a common and chronic neurological disorder that imposes a substantial burden on individuals and society as a whole. The initial diagnosis of epilepsy is associated with costs of diagnostic procedures and inpatient admission. In the further clinical course the majority of patients require an anticonvulsant treatment for an extended period of time and up to 30% of patients are refractory to medical treatment [1] . Economic evaluations are particularly important in patients with newly diagnosed and active epilepsy as they account for a high proportion of total costs [2] [3] [4] [5] . Given the growing resource utilization and limited amount of healthcare resources, it has become essential to gather reliable cost estimates as a scientific basis for resource allocation and health policy decision making. In fact, this has become even more important as the introduction of new antiepileptic drugs, the use of generic medication, the marketing of brain stimulation devices and the resurgence of new surgical treatment options can result in a considerable increase in costs or a shift in the distribution of cost components [6] [7] [8] [9] [10] . Furthermore, epilepsy is still strongly associated with social stigma, reduced employment opportunities and impaired quality of life for patients and their carers, resulting in increased indirect as well as intangible costs [11] [12] [13] [14] [15] .
For economic evaluations either a top-down or a bottom-up approach is utilized to gather cost-of-illness (COI) data [16] . The bottom-up approach is individual-related and preferred when precise cost estimates are required for different subpopulations. It allows epilepsy-specific costs and detailed data on socioeconomic and disease course to be gathered, however such studies are time-consuming and costly as each patient has to be interviewed in detail [17] . On the other hand, top-down studies are useful for high-prevalence illnesses that are well represented in national surveys or insurance databases. However they are incompatible with the stratification of cost by patient or disease characteristics [17] .
To date, previous German COI studies have used a bottom-up approach, with detailed questionnaires, usually spanning over a three-month period, providing information on trends and costdriving factors over time [3, [18] [19] [20] . Due to time-consuming and labour-intensive implementation of such studies they cannot be easily repeated or performed over long periods. Thus, the objective of this bottom-up evaluation was to use an electronic practice management software in daily routine to omit the labour-intensive paper-pencil questionnaires, but to gather, simultaneously, reliable, long-term disease and COI data in patients with epilepsy.
Patients and methods

Study setting and design
The evaluation was performed at six neurological practices providing outpatient care throughout Germany in the cities of Alzenau (18,491 inhabitants), Bielefeld (327,199), Dresden (517,765), Grü nstadt (13,069), Neukirchen-Vluyn (27, 689) and Stuttgart (591,015), population data as of year 2011 (www. destatis.de).
The study population consisted of consecutive outpatients, 18 years of age or older, with an established diagnosis of epilepsy, who gave informed consent to electronic clinical data processing and evaluation. The diagnosis was based on the definitions proposed by the International League Against Epilepsy and the International Bureau for Epilepsy [21] . The electronic data collection was established in 2009 and patients were evaluated if a full data set was available for the evaluation period between 1st January 2011 and 31st December 2011. Patients were excluded when the diagnosis of epilepsy could not be determined without doubt.
Patients and cost assessment
Data on the epilepsy syndrome, concomitant diseases, MRI and EEG findings, socioeconomic status, current antiepileptic drugs (AED) and current seizure frequency were provided by the treating neurologist and entered into an electronic practice management software. For that purpose the practice management software was equipped with the modular designed electronic expert system EPIScout 1 (epilepsy scout). The EPI-Scout 1 software (Desitin Arzneimittel GmbH, Hamburg; Medomus Technologien & Services GmbH, Cologne, Germany; www.medomus.de/technologien/ software/episcout.php) supports the neurologist to orient themself to the evidence-based guidelines for the diagnosis and the treatment of patients with epilepsy and offers the possibility to document case-related clinical action, either for exchange with cooperation partners or towards payers. The software was developed in collaboration with the Department of Epileptology, University of Bonn and a working group of BVDN and BDN (Federal Associations of German Neurologists) [22] .
At each visit the patients were asked by the treating neurologist about epilepsy-related direct and indirect costs. To facilitate the survey only established main direct cost components, including inpatient hospital and rehabilitation care, neurological outpatient service and drug costs due to epilepsy, were recorded and evaluated according to German recommendations for performing health economic evaluations [23] [24] [25] . The aim of this evaluation was to calculate the genuine costs due to epilepsy and not costs that may be triggered by other diseases not related to epilepsy. Therefore, patients were asked in detail whether or not the medication, service or resource were used specifically for epilepsy. The costs of formal and informal care are based on the three nursing care levels (Pflegestufen) approved to the patient by the statutory long-term care insurance (Pflegeversicherung, PV). Former studies [18, 19] indicated that nursing costs were mainly not related to the epilepsy but to a handicap caused by the underlying disease, such as stroke, dementia or cancer. Therefore, we did not considered these nursing costs as due to epilepsy in this evaluation.
The evaluation of costs was performed by means of a bottom-up approach from the perspective of the statutory health insurance (Gesetzliche Krankenversicherung, GKV). Averaged drug costs were obtained from prescription reports [26] . Costs for inpatient care (hospitalization and rehabilitation) were calculated based on daily charges and the German Diagnosis Related Groups (2011, G-DRG; www.g-drg.de). The charges for outpatient care were obtained from the official German doctors' fee scale (Einheitlicher Bewertungsmaßstab, EBM) [27] . Other direct costs as laboratory investigations of imaging were not evaluated in this study. Indirect costs for lost productivity due to days off were evaluated using the human capital approach for patients younger than 65 years. According to the Federal Statistical Office (www.vgrdl.de) the mean gross income was s36,213 in 2011. All costs were calculated for the evaluation period of one year and are provided in 2011 Euro (s). For further details of the cost calculations, see previous studies [3, 28] .
Data entry and statistical analysis
Data entry was performed by each neurologist using the electronic practice management and EPI-Scout 1 software. For further evaluation and processing the data was exported and anonymized by an independent company to comply with data protection regulations [22] .
Statistical analyses were performed using IBM SPSS Statistics 21 (SPSS Inc., Chicago, IL, USA). Cost data are presented as mean AE standard deviation (SD), minimum, maximum and median or percentages where appropriate. In addition, 95% confidence intervals (C.I.) are provided using the bootstrap method according to the biascorrected accelerated (bca) approach, taking into account the fact that most cost variables are right-skewed [29] . Comparisons between groups were performed using the Mann-Whitney test or KruskalWallis test. When appropriate, post hoc comparisons (Holm-Bonferroni) were reported and p-values were corrected.
Results
Clinical and sociodemographic characteristics
During the study period 359 (170 male (47.4%); 189 female) consecutive outpatients treated for epilepsy by neurologists in outpatient offices were recruited. The mean age was 50.5 AE 20.7 years (range 18-99 years). Half of the patients suffered from focal epilepsy (n = 186, 51.8%) the remaining from idiopathic generalized epilepsies (n = 56, 15.6%) and other or unknown epilepsy syndromes (n = 117, 32.6%). The majority of patients were in long-term seizure remission for more than one year (n = 200, 55.7%) and in more than two-thirds AED monotherapy (n = 248, 69.1%) was used. Table 1 shows detailed clinical characteristics. None of the surveyed patients died during the study period. Further socio-demographic characteristics in terms of marital status, residential situation, employment status, disability level, nursing needs and reported difficulties in daily life are presented in Table 2 . Table 3 shows the epilepsy-specific costs of patients during a one-year evaluation period in 2011. Total annual direct costs amounted to s1698 (SD s2247, range s52-15,377) per patient, with anticonvulsants (59.9% of total direct costs) and hospitalization (30.0%) as the main cost factors. Anticonvulsant monotherapy was associated with mean costs of s651 (n = 248) with levetiracetam (mean annual costs s1507, n = 59), lamotrigine (s257, n = 48), valproate (s203; n = 42), carbamazepine (s140; n = 24) and oxcarbazepine (s759; n = 19) as the main five monotherapies of choice.
Direct and indirect costs
During the evaluation period in 2011 fifty patients (13.9%) were admitted to a hospital for 1-29 days (mean hospital stay 8.1 days) with mean costs of s3650 per admission. Nine patients (2.5%) were admitted for rehabilitation to a hospital for 9-48 days (mean hospital stay 22.4 days) with mean costs of s3973 per admission.
The estimate of mean indirect costs was based on patients with a working age of below 65 years. This amounted to 252 patients (70.2%) of working age, and indirect annual costs due to days off amounted to s745 (SD s3587) per patient. Thirty patients (11.9%) had to take days off due to seizures. The mean annual duration of work absenteeism was 4.8 AE 24.6 days (range: 0-230). Table 4 presents each cost factor for patients in seizure remission of more than one year and for patients with active epilepsy.
Prescription patterns and medication costs
Costs and daily dosages of different AEDs are listed in Table 5 .
The mean AED costs were s1017 (SD s1224, range s23-8334) per one year. Levetiracetam (31%), lamotrigine (26%) and valproate (24%) were the drugs prescribed most frequently. Sixty-nine per cent of the patients received AED in monotherapy. Zonisamide, lacosamide and levetiracetam were associated with the highest costs, along with infrequently prescribed AEDs such as eslicarbazepine acetate (n = 2), retigabine (n = 1) or vigabatrin (n = 1). The proportion of enzyme-inducing anticonvulsants was 18.1% (89 out of 491 prescribed drugs). Likewise the share of so-called 'older' AEDs was 35.8% (176/491).
Cost-driving factors
Potential cost-driving factors were identified by univariate analysis as well as post hoc tests and are presented in Table 6 . We found a positive correlation of seizure frequency with increased medication, hospitalization, and direct and indirect costs. Epilepsy syndrome and gender did not influence costs in this analysis. A recent diagnosis of epilepsy in the first two years correlates with higher hospitalization and indirect costs than an established diagnosis of more than three years. Analysis of total direct (p = 0.057), AED (p = 0.087), hospital (p = 0.371) and indirect (p = 0.577) costs did not reveal a significant correlation with the treating neurologist.
Anticonvulsant treatment in patients aged 65 years and older was associated with lower drug costs. Elderly patients aged 65 years and older were treated mainly with monotherapy (92/107; 86%) and were in seizure remission (61/107; 57%). Levetiracetam (mean annual costs s1462, n = 33), carbamazepine (s104; n = 16); phenytoin (s66; n = 14), gabapentin (s374; n = 13) and valproate (s220, n = 13) were the five most prescribed drugs in the elderly.
Discussion
This study is the first evaluation to gather annual disease and COI data in patients with epilepsy using an electronic practice management software in daily routine. We were able to present recent data in 2011 prices and tariffs and confirm previous studies showing the difference in health-care utilization by patients in seizure remission and those with active epilepsy. Furthermore we were able to demonstrate high hospitalization and indirect costs due to days off in the first two years upon diagnosis of epilepsy. This is likely due to inclusion of patients with newly diagnosed epilepsy causing high inpatient and indirect costs upon diagnosis, which is in line with previous long-term studies [30, 31] . Comparison of the presented prescription patterns with previous German evaluations from 2003 [3] , 2008 [19] and 2009 [32] , demonstrates an increase in the prescription of 'newer' drugs and decrease in prescription of enzyme-inducing anticonvulsants.
This study was able to include a large subgroup (n = 107) of elderly patients, which tend to be neglected in field studies. Interestingly, anticonvulsant treatment in the elderly > 65 years was associated with lower costs as compared to patients aged 18-65 years. This subgroup is mainly treated with monotherapy (86%) as compared to patients aged 18-65 years with 62% on monotherapy (156/252); however, the proportion of seizure-free patients is similar, with 56% and 57% in both groups. Older AEDs such as carbamazepine, phenytoin and valproate are still widely used, as well as gabapentin which was formerly considered as the drug of choice in the elderly. This is in keeping with evaluations on a national level which still show a predominance of older AEDs such as carbamazepine, valproate, phenytoin and primidone being prescribed to the elderly [32] . This could be regarded as inappropriate treatment in this age group. However, a recent study of elderly epilepsy patients showed that elderly with chronic epilepsy seem to continue their treatment with phenytoin, carbamazepine and valproate, while a large proportion of patients are on lamotrigine and levetiracetam [33] . In contrast, those elderly with late-onset epilepsy are often started on levetiracetam or gabapentin [33] . Probably, in the course of time, mainly newer AEDs will be prescribed to the elderly with both chronic and lateonset epilepsies. On the other hand elderly patients caused higher costs for hospitalization possibly reflecting the need of admissions in the presence of frailty and other comorbidities.
The direct medical costs in our study were mainly caused by AEDs and hospitalization. The increasing utilization of newer and cost-intensive AEDs, such as levetiracetam is in line with recent studies confirming this trend towards an increased usage of newer AEDs [31] [32] [33] [34] . This finding explains the high costs for anticonvulsants and confirms other recent COI studies [18, 34, 35] , which showed that AEDs were becoming the main contributor to direct costs. However, inpatient costs are still a major cost component and studies with a top-down approach from Denmark [36] and the United States [37, 38] proved hospitalization to be the major direct cost factor. Possibly, cost-intensive patients with status epilepticus [39, 40] and patients undergoing video-EEG monitoring or epilepsy a Mean AE standard deviation. b Enzyme-inducing AEDs: carbamazepine, phenobarbital, primidon, phenytoin; 'old' AEDs: valproate, carbamazepine, phenobarbital, primidon, phenytoin. c Other prescribed AEDs were pregabalin (n = 6), clobazame (n = 3), sultiame (n = 3), eslicarbazepinacetate (n = 2) ethosuximide (n = 2), tiagabine (n = 2), retigabine (n = 1) and vigabatrin (n = 1).
Table 6
Cost and cost components stratified by potential cost-driving factors. surgery are neglected in bottom-up studies that recruit outpatients only. Studies with a top-down approach have the advantage of including all patients with epilepsy, irrespective of their ability to participate in field studies. However, it remains difficult to distinguish between epilepsy-specific costs and costs for comorbidities. In both studies from the United States [37, 38] epilepsyrelated costs for AEDs and claims for epilepsy or convulsions diagnoses accounted for only 32-46% of excess direct costs. Overall, these cost estimates rather represent the average costs of patients with epilepsy than the epilepsy-specific costs. Overall, the ongoing shift in direct cost components in our and other studies suggests that the costs of AEDs and hospitalization are continuously changing and depend on the research setting and health systems. On the one hand, the introduction of generic formulations will surely be associated with further decreasing AED costs. This is especially true for levetiracetam and lamotrigine, which are the drugs of choice in our study. On the other hand, the development of hospitalization costs is rather difficult to forecast and will need further evaluation.
We were able to demonstrate that electronic practice management software can easily be used to perform long-term health economic evaluations with a bottom-up approach. By that means time-consuming and labour-intensive implementation of field studies can be avoided while repeated or long-term evaluations are facilitated. Further use of electronic seizure diaries with direct information from the patient may allow the assessment of the clinical course in individual patients to be improved. Electronic seizure diaries have been proved to be reliable tools for clinical [41, 42] and health economic evaluations [43] . The combination of both physician-and patient-based electronic databases will facilitate performing less expensive studies, but at the same time simplify large, prospective and multicentre clinical trials.
Despite the careful study design, this COI study suffers from certain limitations inherent to such investigations. In order to collect data regarding several direct cost components and indirect costs, the patients were asked about resource consumption at each visit and the possibility of incomplete patient recall cannot be excluded, which could have resulted in an underestimation of costs and a large variability in cost estimates. Also we did not record in detail all possible costs due to epilepsy-related comorbities (e.g. depression, osteoporosis) or AED use [44] , unless they resulted in a hospital admission. Due to recruitment from neurologists in private practice there might be a bias towards a referral population leading to higher costs. Further limitations of our study were due to the calculation of indirect costs using the human capital approach. In the current situation of underemployment in the general population, indirect costs may not exactly reflect the burden on society and may be overestimated [45] . However, due to the limitations of the friction cost approach [46] , we retained the human capital approach, which is in accordance with the German and international recommendations for performing health economic evaluations [25] .
Conclusions
We were able to demonstrate that electronic practice management software can easily be used to perform long-term health economic evaluations with a bottom-up approach.
Future studies should evaluate the development of direct cost components with a focus on hospitalization and anticonvulsants. From the societal perspective, major efforts should focus on the reduction of seizures for maintaining quality of care and reducing the need for hospitalization in epilepsy patients, thus improving the life quality of patients.
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